These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 22584670)
1. An inhibitor of transforming growth factor beta type I receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy. Ohsawa Y; Okada T; Nishimatsu S; Ishizaki M; Suga T; Fujino M; Murakami T; Uchino M; Tsuchida K; Noji S; Hinohara A; Shimizu T; Shimizu K; Sunada Y Lab Invest; 2012 Aug; 92(8):1100-14. PubMed ID: 22584670 [TBL] [Abstract][Full Text] [Related]
2. The Inhibitory Core of the Myostatin Prodomain: Its Interaction with Both Type I and II Membrane Receptors, and Potential to Treat Muscle Atrophy. Ohsawa Y; Takayama K; Nishimatsu S; Okada T; Fujino M; Fukai Y; Murakami T; Hagiwara H; Itoh F; Tsuchida K; Hayashi Y; Sunada Y PLoS One; 2015; 10(7):e0133713. PubMed ID: 26226340 [TBL] [Abstract][Full Text] [Related]
3. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. Ohsawa Y; Hagiwara H; Nakatani M; Yasue A; Moriyama K; Murakami T; Tsuchida K; Noji S; Sunada Y J Clin Invest; 2006 Nov; 116(11):2924-34. PubMed ID: 17039257 [TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Shinto O; Yashiro M; Kawajiri H; Shimizu K; Shimizu T; Miwa A; Hirakawa K Br J Cancer; 2010 Mar; 102(5):844-51. PubMed ID: 20145621 [TBL] [Abstract][Full Text] [Related]
5. Caveolin-3 deficiency associated with the dystrophy P104L mutation impairs skeletal muscle mitochondrial form and function. Shah DS; Nisr RB; Stretton C; Krasteva-Christ G; Hundal HS J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):838-858. PubMed ID: 32090499 [TBL] [Abstract][Full Text] [Related]
9. The Caveolin-3 P104L mutation of LGMD-1C leads to disordered glucose metabolism in muscle cells. Deng YF; Huang YY; Lu WS; Huang YH; Xian J; Wei HQ; Huang Q Biochem Biophys Res Commun; 2017 Apr; 486(2):218-223. PubMed ID: 28232187 [TBL] [Abstract][Full Text] [Related]
10. Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice. Shinto O; Yashiro M; Kawajiri H; Shimizu K; Shimizu T; Miwa A; Hirakawa K Cancer Sci; 2010 Aug; 101(8):1846-52. PubMed ID: 20518790 [TBL] [Abstract][Full Text] [Related]
12. Expression of the muscular dystrophy-associated caveolin-3(P104L) mutant in adult mouse skeletal muscle specifically alters the Ca(2+) channel function of the dihydropyridine receptor. Weiss N; Couchoux H; Legrand C; Berthier C; Allard B; Jacquemond V Pflugers Arch; 2008 Nov; 457(2):361-75. PubMed ID: 18509671 [TBL] [Abstract][Full Text] [Related]
13. Cell-type specific regulation of myostatin signaling. Kemaladewi DU; de Gorter DJ; Aartsma-Rus A; van Ommen GJ; ten Dijke P; 't Hoen PA; Hoogaars WM FASEB J; 2012 Apr; 26(4):1462-72. PubMed ID: 22202673 [TBL] [Abstract][Full Text] [Related]
14. Syntenin regulates TGF-β1-induced Smad activation and the epithelial-to-mesenchymal transition by inhibiting caveolin-mediated TGF-β type I receptor internalization. Hwangbo C; Tae N; Lee S; Kim O; Park OK; Kim J; Kwon SH; Lee JH Oncogene; 2016 Jan; 35(3):389-401. PubMed ID: 25893292 [TBL] [Abstract][Full Text] [Related]
15. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model. Rhodes SD; Wu X; He Y; Chen S; Yang H; Staser KW; Wang J; Zhang P; Jiang C; Yokota H; Dong R; Peng X; Yang X; Murthy S; Azhar M; Mohammad KS; Xu M; Guise TA; Yang FC J Bone Miner Res; 2013 Dec; 28(12):2476-89. PubMed ID: 23703870 [TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis. Rosendahl A; Speletas M; Leandersson K; Ivars F; Sideras P Int Immunol; 2003 Dec; 15(12):1401-14. PubMed ID: 14645149 [TBL] [Abstract][Full Text] [Related]
17. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Inman GJ; Nicolás FJ; Callahan JF; Harling JD; Gaster LM; Reith AD; Laping NJ; Hill CS Mol Pharmacol; 2002 Jul; 62(1):65-74. PubMed ID: 12065756 [TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor beta (TGF-beta) signaling is regulated by electrical activity in skeletal muscle cells. TGF-beta type I receptor is transcriptionally regulated by myotube excitability. Ugarte G; Brandan E J Biol Chem; 2006 Jul; 281(27):18473-81. PubMed ID: 16682418 [TBL] [Abstract][Full Text] [Related]
19. Smad2 and 3 transcription factors control muscle mass in adulthood. Sartori R; Milan G; Patron M; Mammucari C; Blaauw B; Abraham R; Sandri M Am J Physiol Cell Physiol; 2009 Jun; 296(6):C1248-57. PubMed ID: 19357234 [TBL] [Abstract][Full Text] [Related]
20. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors. Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]